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KEY POINTS SUMMARY 42 
 43 
• Sherpa have lived in the Nepal Himalaya for 25-40 thousand years and display positive 44 
physiological adaptations to hypoxia 45 
• Sherpa have previously been demonstrated to suffer less negative cerebral side effects of ascent to 46 
extreme altitude, yet little is known as to whether or not they display differential regulation of 47 
oxygen delivery to the brain compared to lowland natives 48 
• We demonstrate that Sherpa have lower brain blood flow during ascent to and acclimatization at 49 
high-altitude compared to lowlanders and that this difference in flow is not attributable to factors 50 
such as mean arterial pressure, blood viscosity and pH 51 
• The observed lower cerebral oxygen delivery in Sherpa likely represents a positive adaptation 52 
that may indicate a cerebral hypometabolic conservation of energy at altitude and/or decrease 53 




Debilitating side effects of hypoxia manifest within the central nervous system; however, high-altitude 58 
natives of the Tibetan plateau, the Sherpa, experience negligible cerebral effects compared to lowland 59 
natives at extreme altitude. Phenotypical optimization of the oxygen cascade has been demonstrated in the 60 
systemic circulation of Tibetans and Sherpa, likely underscoring their adapted capacity to thrive at altitude. 61 
Yet, little is known as to how the cerebral circulation of Sherpa may be adapted. To examine potential 62 
differences in cerebral oxygen delivery in Sherpa compared to lowlanders we measured arterial blood gases 63 
and global cerebral blood flow (duplex ultrasound) during a nine-day ascent to 5050m. Although cerebral 64 
oxygen delivery was maintained during ascent in lowlanders, it was significantly reduced in the Sherpa at 65 
3400m (-30.3±21.6%; P<0.01) and 4371m (-14.2±10.7%; P=0.03). Furthermore, linear mixed effects 66 
modeling indicated that independent of differences in mean arterial pressure, pH and blood viscosity, race 67 
accounts for an approximate 100mL · min-1 (~17-34%) lower CBF in Sherpa compared to lowlanders across 68 
ascent to altitude (P=0.046). To ascertain the role of chronic hypoxia independent of the ascent, Sherpa 69 
who had not recently descended were also examined at 5050m. In these Sherpa, cerebral oxygen delivery 70 
was also lower compared to lowlanders (~22% lower; P<0.01). We highlight new information about the 71 
influence of race and genetic adaptation in the regulation of cerebral oxygen delivery. The lower cerebral 72 
oxygen delivery in the Sherpa potentially represents a positive adaptation considering Sherpa endure less 73 
deleterious cerebral consequences than lowlanders at altitude.  74 
 75 
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The dramatically low atmospheric oxygen levels of the Tibetan Plateau represent one of the most hostile 79 
living conditions of modern human habitation. While this environment is debilitating for most humans, and 80 
may be fatal for those who ascend too high and too fast, it has been inhabited for millennia (30,000-40,000 81 
years) by a lineage of Sherpa (Zhang & Li, 2002; Aldenderfer, 2011; Zhang et al., 2018). The Sherpa, a 82 
highlander population of the Nepalese Khumbu region that shares a common genetic origin with Tibetans 83 
(Lu et al., 2016; Zhang et al., 2017), have clearly evolved under the selection pressures imposed by hypoxia 84 
and are consequently better suited for life at altitude than lowland natives (Lahiri & Milledge, 1965; Moore, 85 
2017). Of critical importance in the setting of hypoxia is the oxygen sensitive brain, which due to a high 86 
metabolic demand and limited substrate storage is highly susceptible to metabolic deficiency and ensuing 87 
hypoxic damage [reviewed in: (Bailey et al., 2009)]. Therefore, increases in cerebral blood flow (CBF) are 88 
integral to maintain oxygen delivery to the brain (CDO2) in the face of hypoxemia and a reduced arterial 89 
oxygen content (CaO2). 90 
 91 
While several examples of phenotypical adaptations distinct from those in lowlanders have been observed 92 
in the oxygen cascade of Tibetans, such as a higher nitric oxide bioavailability (Beall et al., 2001; Erzurum 93 
et al., 2007), increased skeletal muscle capillary density (Beall, 2007), and improved muscle energetics in 94 
Sherpa (Horscroft et al., 2017), little is known relative to potential adaptations in cerebral oxygen 95 
delivery/utilization [for review see: (Jansen & Basnyat, 2011; Gilbert-Kawai et al., 2014)]. Tibetans may 96 
display a “high flow” phenotype to maintain oxygen delivery to various peripheral tissues in the presence 97 
of relatively normal arterial oxyhaemoglobin saturation (SaO2) and haemoglobin concentrations [Hb] that 98 
are comparable to lowlanders at altitude (Beall, 2007). However, this high flow phenotype appears to be 99 
isolated to the arm, as femoral blood flow does not differ between lowlanders and Sherpa at rest (Ruggiero 100 
et al., 2018; Tremblay et al., 2018). Therefore, it is reasonable to expect the Sherpa brain may possess its 101 
own unique phenotype for the regulation of oxygen delivery. Preliminary evidence ostensibly indicates a 102 
high flow adaptation in the brain due to elevated internal carotid artery (ICA) velocity in Tibetan natives 103 
compared to lowlanders at 3658 m (Huang et al., 1992). However, a recent cross-sectional study 104 
demonstrated lower CDO2 in Tibetans than in Han Chinese at sea level and at 3658 m (Liu et al., 2016). 105 
Given that velocity is a poor index of flow (and therefore CDO2) in the setting of altered intra-cranial 106 
cerebral arterial diameter (Ainslie & Hoiland, 2014; Hoiland & Ainslie, 2016), which occurs at altitude 107 
(Wilson et al., 2011; Imray et al., 2014; Willie et al., 2014a), previous theories related to a high-flow 108 
adaptation in the Sherpa brain (Huang et al., 1992; Gilbert-Kawai et al., 2014) need to be re-considered. 109 
Elucidation of hypoxia tolerant adaptation in humans may provide insight into potential therapeutic targets 110 
in chronic hypoxic diseases and further our basic understanding of human responses to low oxygen 111 
conditions. 112 




It is well established that CDO2 is maintained during ascent and at altitude in lowlanders [reviewed in: 114 
(Ainslie & Subudhi, 2014)]. However, volumetric CBF and CDO2 have yet to be compared between 115 
lowlanders and Sherpa following a short duration at altitude (e.g., days). It is also unknown if CBF in 116 
lowlanders responds differentially to that of Sherpa during graded ascent to altitude. During ascent to and 117 
upon arrival at 5050 m, we hypothesized that CBF and CDO2 would be lower in Sherpa compared to 118 
lowlanders. To examine these novel hypotheses, Sherpa and lowlanders were studied using a longitudinal 119 
experimental design during ascent to altitude. Further, to determine the influence of partial de-120 
acclimatization on CBF regulation, Sherpa recently exposed to altitude for a short duration (those who 121 
ascended) and long duration (those residing at altitude) were compared to lowlanders using a cross-sectional 122 
design following arrival at 5050 m. Further mechanistic insight was also obtained within these groups via 123 
the concurrent assessment of established factors in the regulation of CBF [e.g. arterial blood gases (Kety & 124 
Schmidt, 1948), mean arterial pressure, MAP (Lucas et al., 2010; Numan et al., 2014) and blood viscosity 125 
(Hoiland et al., 2016)].  126 
 127 
 128 
MATERIALS AND METHODS 129 
 130 
Ethical Approval 131 
 132 
This study was approved by the Clinical Research Ethics Board of the University of British Columbia (H16-133 
01028) and the Nepal Health Research Council. All lowlander participants gave written informed consent 134 
in English prior to participating. All Sherpa participants read an in-depth study information form, spoke 135 
with a Nepalese physician and gave written informed consent in Nepalese prior to participating. This study 136 
conformed to the standards set by the Declaration of Helsinki, except for registration in a database. 137 
 138 
Study participants 139 
 140 
This study involved the recruitment of three distinct subject groups. First, the lowlander group comprised 141 
of 21 (1 female) healthy individuals (mean±standard deviation, Age: 29±6 years; body mass index (BMI): 142 
23±2kg/m2; height: 179±6 cm) who were recruited at the University of British Columbia’s Okanagan 143 
campus and were part of the research team. All lowlander participants were free of cardiovascular, 144 
respiratory and neurological diseases and were non-smokers.  145 
 146 
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The second group of participants comprised of 12 high-altitude Sherpa (Age: 34±11, BMI: 24±4; height: 147 
167±7 cm). These Sherpa were of Tibetan lineage. The Sherpa participants were recruited from local 148 
villages in the Solukhumbu Valley (Table 1) and descended to Kathmandu prior to experimental testing 149 
(see Experimental Overview). Four Sherpa were current smokers, with an average of 1.3±1.1 pack years. 150 
The Sherpa were free of cardiovascular, respiratory and neurological diseases. This cohort of Sherpa is 151 
referred to as the “Ascent Sherpa” throughout the manuscript. Notably, three of the Sherpa in this group 152 
had summited Mount Everest (8848 m) in the previous year, while the remaining Sherpa had reached 153 
maximum altitude of 4800 m to 7800 m (median: 5545 m) in the last year.  154 
 155 
The third group of participants included 11 Sherpa of Tibetan lineage (Age: 23±7, BMI: 21±2; height: 156 
170±6 cm) that were recruited from local villages in the Solukhumbu Valley (Table 1); however, unlike the 157 
Ascent Sherpa, these Sherpa were recruited while the research team was at the Ev-K2-CNR Pyramid 158 
laboratory. Therefore, these Sherpa did not descend to Kathmandu prior to testing. Five Sherpa were current 159 
smokers, with an average of 0.4±0.1 pack years. All Sherpa were free of cardiovascular, respiratory and 160 
neurological diseases. This cohort of Sherpa is referred to as the “Altitude Sherpa” throughout the 161 
manuscript. Notably, two of the Sherpa in this group had summited Mount Everest in the previous year, 162 
while the remaining Sherpa had reached a maximum altitude of 4200 m to 5545 m (median: 5300 m).  163 
 164 
Experimental Overview 165 
 166 
The logistics of the UBC-Nepal Expedition have been detailed extensively elsewhere (Willie et al., 2018), 167 
therefore, only features of the expedition pertinent to the current study will be outlined. All lowlander 168 
participants spent 3-9 days in Kathmandu (1400 m) prior to flying to Lukla (2860 m) to begin the ascent to 169 
the EV-K2-CNR Pyramid Research laboratory (5050 m), while the Ascent Sherpa group descended to 170 
Kathmandu and remained there for 5-15 days (median: 7) prior to flying to Lukla with the lowlanders. 171 
Ascent to the Pyramid Laboratory took place over a slow and safe 9-day trekking protocol without the use 172 
of any acute mountain sickness prophylactics (e.g., acetazolamide). Participants spent one night in Monjo 173 
(2800 m), three nights in Namche Bazaar (3400 m), one night in Deboche (3820 m), and then three nights 174 
in Pheriche (4371 m) followed by the final trekking day to 5050 m. 175 
 176 
In Kathmandu prior to the ascent and on the day following arrival to Namche, Pheriche, and the Pyramid 177 
laboratory, all participants underwent experimental measurement of arterial blood gases, venous blood 178 
viscosity, MAP, heart rate (HR), and CBF. These measurements are detailed below (see Experimental 179 
Measures). 180 
 181 
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Once the ascent study was completed, a second experimental protocol was conducted on the Altitude Sherpa 182 
group. The Altitude Sherpa group had not descended to low altitude (<2800 m) in the previous 6 months, 183 
were living at high-altitude prior to arrival at the Pyramid, ascended from 3400-4200 m to 5050 m in 1-2 184 
days, and were tested 1-2 days following arrival. This timeline was utilized to match the time after arrival 185 
of testing to the lowlander and Ascent Sherpa groups (i.e. 1 day following arrival to 5050 m). They 186 
completed the same experimental protocol as the lowlanders and Ascent Sherpa (described below). 187 
 188 
Experimental Measures 189 
 190 
Following 10-minutes supine rest at each location during the ascent and after approximately 2 weeks at 191 
high-altitude when the Altitude Sherpa were tested, arterial blood samples were taken from the radial artery. 192 
A 23-G self-filling syringe (SafePico, Radiometer) was advanced into the radial artery under local 193 
anesthesia (lidocaine, 1.0%) and ultrasound guidance (Terason, uSmart 3300). Approximately 1mL of 194 
blood was withdrawn anaerobically and immediately assessed using an arterial blood gas analyzer for the 195 
partial pressure of arterial oxygen (PaO2), the partial pressure of arterial carbon dioxide (PaCO2), pH, 196 
bicarbonate (HCO3-), [Hb], and HCT (i-STAT 1, Abbott Point of Care). Further, following venipuncture of 197 
the median ante-cubital vein (21G needle, BD Vacutainer eclipse) 2mL of blood was collected into a lithium 198 
heparin vacutainer. From this venous sample, 1mL of whole blood was used to measure blood viscosity 199 
(Brookfield DVST Viscometer) at a shear rate of 225 s-1 with temperature controlled at 37.0°C.  200 
 201 
Blood velocity and vessel diameter of the ICA and vertebral artery (VA) were measured using a 10MHz 202 
multi-frequency linear array duplex ultrasound (Terason T3200, Teratech, Burlington, MA) according to 203 
published technical recommendations (Thomas et al., 2015). Arterial diameter was measured with B-mode 204 
imaging while pulse-wave mode was used to simultaneously measure peak envelope blood velocity. The 205 
ICA diameter and velocity were in most cases measured at least 1.5 cm distal to the common carotid 206 
bifurcation to eliminate recordings of turbulent and retrograde flow, while VA diameter and velocity were 207 
measured between C4-C5, C5-C6, or proximal to entry into the vertebral column. The location was 208 
determined on an individual basis in an attempt to select the most reproducible measures, with the same 209 
location repeated within participants and between testing dates. Images were recorded and stored as video 210 
files for offline analysis using automated edge detection software (Woodman et al., 2001) following study 211 
completion. No less than a one-minute video was used for the assessment of ICA and VA flow. Volumetric 212 
blood flow was calculated using the following formula: 213 
 214 
𝐼𝐶𝐴 𝑜𝑟 𝑉𝐴 𝑓𝑙𝑜𝑤 = (0.5 ∙ 𝑃𝑒𝑎𝑘 𝑒𝑛𝑣𝑒𝑙𝑜𝑝𝑒 𝑣𝑒𝑙𝑜𝑐𝑖𝑡𝑦) ∙ (𝜋 ∙ (0.5 ∙ 𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟)2 ) 215 
 216 
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The gCBF was estimated as twice the sum of the unilateral ICA and VA flow measurements. During the 217 
ascent, MAP was calculated as the average of three automated measurements on the brachial artery (Life 218 
Source, UA-767FAM). In the experimental trials following 2-weeks at the Pyramid, MAP was determined 219 
as the average of two manual sphygmomanometric measurements. 220 
 221 
In an attempt to better understand the underlying physiology regulating gCBF in Sherpa and lowlanders we 222 
measured cerebral vascular reactivity to CO2 using the hyperoxic rebreathe technique (Fan et al., 2010). As 223 
we were unable to collect CO2 reactivity data during our 2016 expedition, this particular data set was taken 224 
from 13 lowlanders and five Sherpa on our 2008 expedition to Nepal (Lucas et al., 2011). The lowlanders 225 
from our 2008 expedition underwent a similar ascent protocol, and were tested following >2 weeks 226 
acclimatization at 5050 m (Lucas et al., 2011). The Sherpa subjects from the 2008 expedition were tested 227 
under similar conditions as the Altitude Sherpa from the 2016 expedition in that they had not previously 228 




In an attempt to account for the influence of changes in blood pressure on CBF upon ascent to high-altitude, 233 
we calculated cerebrovascular conductance (CVC) as gCBF divided by MAP (i.e. CVC = gCBF/MAP). 234 
Shear stress in the ICA and VA were calculated as the product of shear rate (s-1) and venous blood viscosity 235 
(cP). Shear rate was determined as 4 times velocity divided by diameter (i.e. Shear rate = 4 * velocity / 236 
diameter). Cerebral oxygen delivery (mL · min-1) was calculated as the product of CaO2 (mL · dL-1) and 237 
gCBF (mL · min-1) divided by 100 (i.e., CDO2 = CaO2 · gCBF / 100). 238 
 239 
Statistical Analyses 240 
 241 
Data from the ascent were analyzed using a linear mixed effects model with a compound symmetry repeated 242 
measure co-variance structure. A linear mixed effects model was ran for each variable (e.g., those in figure 243 
1 and table 2). The fixed effects were altitude and race (with altitude as a repeated effect) while subjects 244 
were included as a random effect. When significant main effects were detected, Bonferroni corrected post-245 
hoc tests were used to make pairwise comparisons. Significance was assumed at P<0.05. There was no 246 
difference in the primary outcome variables between current and non-smokers in either Sherpa group.  247 
 248 
As there were differences between lowlanders and Sherpa relative to several factors known to influence 249 
CBF (see Results), we also ran a linear mixed effects model for gCBF with MAP, pH, and viscosity as co-250 
variates alongside altitude and race as fixed effects and subjects as a random effect. The selected variables 251 
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were chosen as they are considered important regulators of CBF in humans (Willie et al., 2014b) and they 252 
improved the model fit, as determined by the -2 log likelihood indicating their acceptability in the model. 253 
When assessed for colinearity it was found that the covariates were only mildly colinear (all variable 254 
inflation factors < 1.2; note: >4 is considered moderately colinear). Residuals were normally distributed 255 
and equality of variance was confirmed by visually inspecting a residuals versus fitted scatterplot.  256 
 257 
Differences between acclimatized lowlanders, the ascent Sherpa, and altitude Sherpa at 2-weeks were 258 
compared using a one-way ANOVA. When significant main effects were detected, Bonferroni corrected 259 
post-hoc tests were used to make pairwise comparisons. Sherpa versus lowlander cerebral vascular CO2 260 





Arterial and Venous Blood Variables 266 
 267 
All arterial and venous blood data are summarized in Table 2. Notably, CaO2, SaO2, and the PaO2 did not 268 
differ between lowlanders and Sherpa at any high-altitude location. Although a reduction in the PaCO2 was 269 
observed in both groups, PaCO2 was higher in Sherpa at 4371 m and 5050 m (vs. lowlanders P<0.01). 270 
Accordingly, there was a main effect for lower pH in Sherpa across all altitudes (P<0.01). At 1400 m Sherpa 271 
had an elevated haemoglobin concentration ([Hb]) relative to lowlanders (P<0.01), but following an 272 
increase in lowlander [Hb] at 3400 m (P<0.01), there was no difference present between groups throughout 273 
the remainder of the ascent. Both haematocrit (HCT) and venous whole blood viscosity followed the same 274 
pattern as [Hb], with Sherpa HCT and viscosity elevated compared to lowlanders at 1400 m, but not 275 
different during the remainder of ascent. 276 
 277 
Cerebrovascular and Cardiorespiratory Variables 278 
 279 
In lowlanders, global CBF (gCBF) was unchanged from Kathmandu (1400 m) values at 3400 m and 4371 280 
m (+0.4±15.5% & -0.1±21.5%, respectively), but increased by 23.3±26.1% at 5050 m (main effect of 281 
altitude, P<0.01) (Figure 1). Flow through the ICA and VA followed a similar pattern – both were unaltered 282 
at 3400 m or 4371 m, but were elevated by 18.4±26.2% and 24.6±31.9% at 5050 m, respectively (main 283 
effect of altitude, P<0.01). In the Sherpa, gCBF appeared 21.3±24.0% lower at 3400 m compared to 284 
Kathmandu, returned to Kathmandu values by 4371 m (-4.3±8.8%), and was elevated by 13.5±22.3% at 285 
5050 m (main effect of altitude, P<0.01). Regional flow through the ICA and VA appeared to follow 286 
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differential patterns in the Sherpa, with ICA flow reduced by 22.8±21.6% at 3400 m compared to 287 
Kathmandu, returned to Kathmandu values by 4371 m (-5.8±11.1%), and then elevated by 10.0±22.8% at 288 
5050 m. However, VA flow was unaltered at 3400 m (-5.9±44.2%), albeit this response showed substantial 289 
inter-individual variability (see statistical outputs in Figure 1). At 4371 m, VA flow in the Sherpa was 290 
slightly elevated by 10.6±51.2%, with a further significant elevation at 5050 m where VA flow was 291 
20.7±31.8% greater than in Kathmandu (main effect of altitude, P<0.01). There was a significant main 292 
effect of race, with ICA flow, VA flow, and gCBF greater in lowlanders compared to Sherpa across all 293 
altitudes (Figure 1). Changes in blood velocity and diameter of the ICA and VA are summarized in Table 294 
3. Anterior (i.e. ICA flow) versus posterior (i.e. VA flow) distributions of CBF in lowlanders and Sherpa 295 
are presented in Figure 2. Sherpa had a lower posterior distribution of CBF than lowlanders across all 296 
altitudes during ascent (main effect of race, P=0.018). 297 
 298 
There was a significant interaction effect (i.e. altitude * race) for ICA delivery of oxygen (DO2; P=0.008) 299 
but not VA DO2 (P=0.443; Table 3). Collectively, global CDO2 was maintained in the lowlanders during 300 
ascent (Figure 1D). In contrast, Sherpa CDO2 was reduced at 3400 m (-30.3±21.6%; P<0.01), 4371 m (-301 
14.2±10.7%; P=0.03), but was not statistically different from Kathmandu at 5050 m (-12.0±18.0%; 302 
P=0.28). Compared to lowlanders, Sherpa CDO2 was lower at 3400 m (P<0.01), 4371 m (P=0.03), and 303 
5050 m (P<0.01).  304 
 305 
Lowlander mean arterial pressure (MAP) across ascent in lowlanders and Sherpa is summarized in Table 306 
3. The combination of changes in gCBF and MAP lead to a main effect of both altitude (P<0.001) and race 307 
(P<0.001) on CVC (interaction, P=0.166). Lowlander (7.91±1.42 vs. 6.97±1.32 mL · min-1 · mmHg-1) and 308 
Sherpa (5.80±1.32 vs. 4.02±1.15 mL · min-1 · mmHg-1) CVC were reduced at 3400 m compared to 309 
Kathmandu (main effect of altitude, P=0.001). Lowlander and Sherpa CVC were not different from 310 
Kathmandu at 4371 m (7.04±1.58 & 5.22±1.23 mL · min-1 · mmHg-1, respectively) or 5050 m (7.99±1.74 311 
& 6.41±1.64 mL · min-1 · mmHg-1, respectively). 312 
 313 
Covariate Analysis: Linear mixed effects modeling was utilized to determine the significance of race on 314 
CBF at altitude by controlling for important regulators of CBF as covariates. Including MAP, pH, and 315 
viscosity led to the best model fit (-2 log likelihood). As outlined in Figure 3, irrespective of including 316 
covariates into the analysis, race possesses a significant influence on gCBF at altitude (see section 317 
Cerebrovascular and Cardiorespiratory Variables for results of initial linear mixed model). Indeed, race 318 
had a similar effect on gCBF in both models given the similar parameter effects with no covariates (-319 
118.93±47.34; P=0.014) or with the inclusion of MAP, pH and viscosity as covariates (-99.67±48.93; 320 
P=0.046). Further illustrating the significant effect of race as a factor in CBF control at altitude, upon 321 
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controlling for the aforementioned covariates, there was a significant interaction between altitude and race 322 
(P=0.012), with post-hoc tests revealing that gCBF was lower in Sherpa compared to lowlanders at 1400m 323 
(P=0.046), 3400 m (P<0.001), 4371 m (P=0.022) and 5050 m (P=0.001) (Figure 3). Note: the gCBF data 324 
plotted in Figure 1C and Figure 3A are the same, except Figure 1C is the mean± standard deviation of the 325 
raw data whereas Figure 3A is the mean± standard error of the model estimates. The data is reproduced in 326 
Figure 3 for the purpose of easy comparison with the covariate model. 327 
 328 
 329 
Lowlander Comparison to Both the Ascent and Altitude Sherpa 330 
 331 
Comparison of lowlanders to both the Ascent Sherpa and Altitude Sherpa at 5050 m revealed their gCBF 332 
were similarly 24% (P<0.01) and 27% (P<0.01) lower, respectively (Figure 4). While differences in ICA 333 
flow between groups approached statistical significance (main effect, P=0.06), the difference in gCBF 334 
between lowlanders and both Sherpa groups is largely attributable to a 40% (Ascent Sherpa, P<0.01) and 335 
44% (Altitude Sherpa, P<0.01) lower VA flow. This is consistent with the lower posterior CBF distribution 336 
in both Sherpa groups compared to lowlanders at 5050 m (P<0.05 for both; Figure 2). These differences in 337 
CBF - in the face of similar CaO2 values (Table 4) - were reflected in a 21% (P=0.02) and 22% (P<0.01) 338 
lower CDO2 in the Ascent Sherpa and Altitude Sherpa, respectively. Cerebral vascular CO2 reactivity was 339 
not different between Sherpa and lowlanders (5.4±2.1 vs. 5.0±1.1 % · mmHg-1; P=0.77) at 5050 m (Figure 340 





The present study examined the novel hypothesis that CBF and CDO2 would be lower in Sherpa compared 346 
to lowlanders during ascent to high altitude. To address this question, unique comparisons of CBF, CDO2 347 
and related physiological parameters were made between lowlanders and partially de-acclimatized Sherpa 348 
during graded ascent to 5050 m. Further comparisons were made between lowlanders, the Sherpa that had 349 
ascended (Ascent Sherpa), and Sherpa that were residing at altitude prior to travel to the Pyramid 350 
Laboratory (Altitude Sherpa). The primary findings are: 1) gCBF during ascent to high altitude is 351 
significantly lower (17-34%) in the Sherpa with an approximate 100 to 120 mL · min-1 of the difference 352 
in gCBF between lowlanders and Sherpa attributable to factors associated with race; 2) consequently, upon 353 
ascent to high-altitude, CDO2 is higher in lowlanders compared to Sherpa, and higher than both the Ascent 354 
and Altitude Sherpa at 5050 m; 3) CBF distribution to the posterior circulation was lower across all altitudes 355 
during ascent in Sherpa compared to lowlanders, and lower in both Sherpa groups compared to lowlanders 356 
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at 5050 m. Collectively, these data indicate that there is a unique role of race in governing differential CBF 357 
regulation between lowlanders and Sherpa, irrespective of partial de-acclimatization, implicating long-term 358 
(i.e., generational) adaptations in the regulation of CDO2.  359 
 360 
 361 
Cerebral blood flow at altitude: Influence of race  362 
 363 
Our study corroborates recent research demonstrating that Tibetans’ possess lower CBF than lowlanders at 364 
altitude (Liu et al., 2016) (Figures 1; 3 & 4). Although not quantified in this latter study (Liu et al., 2016), 365 
we extend these findings using a longitudinal design to show that these differences are present despite a 366 
similar blood gas profile during ascent between groups. Notably, however, pH was lower, and PaCO2 was 367 
higher in the Sherpa (typically these two factors would increase gCBF in Sherpa relative to lowlanders – 368 
see Potential Mechanism(s) of Reduced CDO2). When lowlander CBF was compared to Sherpa that had 369 
not recently descended to low altitude, lowlander CBF remained higher; therefore, irrespective of recent 370 
time at altitude, Sherpa possess lower CBF than lowlanders. Yet, the recent study by Lui et al., reported 371 
similar CBF at sea level between Tibetans and Han-Chinese (Liu et al., 2016). Our group has also recently 372 
demonstrated that gCBF is lower in Sherpa children compared to lowlander children which, given the 373 
consistently lower CBF across the lifespan, suggests developmental differences do not account for our 374 
observation of lower CBF in Sherpa at high altitude compared to lowlanders (Flück et al., 2017). Further 375 
research, using a longitudinal study design where Tibetans/Sherpa born at sea-level ascend to altitude is 376 
necessary to explicitly determine the influence of Tibetan genetic adaptation on CBF regulation 377 
independent of previous hypoxic exposure. Overall, the lower gCBF in Sherpa during ascent, and in both 378 
Sherpa groups at 5050 m, led to a lower CDO2 in Sherpa compared to lowlanders at every high-altitude 379 
time point. 380 
 381 
Previous studies have indicated a greater preservation of VA flow (i.e. posterior oxygen delivery) relative 382 
to ICA flow (i.e. anterior oxygen delivery) in both high-altitude natives (Liu et al., 2016) and lowlanders 383 
rapidly ascending  to 5260 m (Subudhi et al., 2014). In other words, reactivity of the posterior circulation 384 
to altitude appears greater than the anterior circulation, with posterior oxygen delivery not changing from 385 
normoxic values. These findings are further corroborated by the present study (Figure 1) where posterior 386 
CBF distribution did not decrease during ascent in lowlanders or Sherpa.  However, the Ascent and Altitude 387 
Sherpa demonstrated a lower percentage of gCBF distributed to the posterior circulation across all altitudes 388 
compared to lowlanders (Figure 2). At 5050 m lower posterior CBF distribution appeared to represent the 389 
majority of the lower gCBF in both Sherpa groups compared to lowlanders. This lower percentage 390 
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distribution to the posterior circulation in Sherpa adults is consistent with data in Sherpa children (Flück et 391 
al., 2017). 392 
 393 
 394 
Potential Mechanism(s) of Reduced CDO2 395 
 396 
Several factors that are implicated in the integrative regulation of CBF should theoretically be cause for a 397 
higher – rather than the observed lower - CBF in Sherpa compared to lowlanders in the present study. For 398 
example, higher PaCO2 and MAP alongside a lower pH in Sherpa compared to lowlanders (Table 2) should 399 
theoretically lead to a higher CBF in Sherpa (Kety & Schmidt, 1948; Lucas et al., 2010). Despite these 400 
differences, and that CaO2, [Hb], and blood viscosity were similar throughout ascent, CBF is paradoxically 401 
lower in Sherpa compared to lowlanders. This suggests that simply assessing absolute changes in CBF 402 
alone may lead to a misrepresentation of differences in CBF regulation between lowlanders and Sherpa. 403 
When the contributions of MAP, pH, and viscosity were accounted for statistically as covariates, CBF 404 
became significantly lower in the Sherpa compared to the lowlanders at each altitude. Therefore, 405 
independent of physiological regulators of CBF, race is an important mechanism that underscores the lower 406 
CBF observed in Sherpa compared to lowlanders.  407 
 408 
Race being an independent predictor of gCBF at altitude (~100 mL · min-1; Figure 3; ~15% of resting 409 
lowlander CBF) further affirms that the difference in CBF between groups cannot be explained by our 410 
measured variables. When considering cerebrovascular responsiveness to the aforementioned inputs (e.g. 411 
CaO2, PaCO2, MAP, etc.,) there remains no apparent explanation of reduced CBF and CDO2 in Sherpa 412 
during ascent. For example, cerebrovascular CO2 reactivity is not different between lowlander and Sherpa 413 
at altitude during ascent at 4371 m (Jansen et al., 1999) and following acclimatization to 5050 m (Figure 414 
5). Further, we have demonstrated previously that the cerebrovascular response to driven changes in MAP 415 
(i.e. cerebral autoregulation) does not differ between Sherpa and partially acclimatized lowlanders (Smirl 416 
et al., 2014), although this has not been consistently demonstrated during infusion of the vasoactive drug 417 
phenylephrine (Jansen et al., 2014). However, infusion of a vasoactive drug likely invalidates transcranial 418 
Doppler ultrasound as an index of CBF as used in the aforementioned study by Jansen and colleagues 419 
(Hoiland & Ainslie, 2016). Endothelial function, as indexed in the brachial artery, is greater in Sherpa at 420 
5050m following ascent in the same cohort of individuals tested in this present study (Tremblay et al., 421 
2018). When compared between acclimatized (~2 weeks) lowlanders and Sherpa, endothelial function 422 
appears similar (Lewis et al., 2014). If differences in endothelial function were to manifest similarly in the 423 
cerebral circulation this would be cause for higher CBF. Therefore, potential differences in endothelial, 424 
function is another factor that cannot explain the reduced CDO2 observed in Sherpa during ascent. 425 




While cerebral metabolism does not differ between Sherpa and lowlanders at sea level (Hochachka et al., 427 
1996), it has not been compared between groups following acclimatization or prolonged stay at altitude and 428 
may represent the most tenable mechanism for reduced CDO2. In keeping CDO2 did not differ between 429 
groups at 1400 m where metabolism is apparently not different after a similar duration of de-acclimatization 430 
(Hochachka et al., 1996); however, upon hypoxic exposure (3400 m and above) CDO2 was lower in Sherpa, 431 
which, if coupled to cerebral metabolic demand (as it is at sea-level) (Ainslie et al., 2014), is perhaps related 432 
to some form of hypoxia induced hypometabolism. This may represent a genetic/hypoxic interaction, 433 
whereby adaptive phenotypes only present following exposure to hypoxia (i.e., genotype-phenotype 434 
interaction). Such a hypometabolic adaptation is key for the purposes of oxygen conservation in various 435 
vertebrates such as the crucian carp and some fresh water turtles that possess an ability to reduce cerebral 436 
metabolism among a number of other adaptive physiological processes to tolerate hypoxic and anoxic 437 
environments (Nilsson & Lutz, 2004). A similar hypometabolic response is also observed in elite apnea 438 
divers who display a reduction in cerebral metabolism during long duration apneas (3-7 min) (Bain et al., 439 
2016). Further, greater mitochondrial efficiency has recently been demonstrated in skeletal muscle of 440 
Sherpa compared to lowlanders (Horscroft et al., 2017), which if such a phenomenon is present in cerebral 441 
tissue may be related to the differential flow regulation observed in the present study. However, if the 442 
difference in CDO2 is unrelated to metabolic differences between lowlander and Sherpa (i.e., no difference 443 
in cerebral metabolism), one may expect a role of elevated angiogenesis and capillary density (Xu & 444 
Lamanna, 2006) in Sherpa that allows for a  greater extraction of oxygen. If the case, this would necessitate 445 
less bulk flow to maintain metabolic homeostasis as is seen in skeletal muscle of varying capillary density 446 
(Gayeski et al., 1988), however, one would expect this to be reflected by a higher (not lower as we observed) 447 
cerebrovascular conductance in the Sherpa group. Although these mechanism(s) remain to be established, 448 
it would seem reasonable to suggest that the observed reductions in CDO2 in the Sherpa are adaptive rather 449 
than maladaptive (see Significance and Implications).  450 
 451 
 452 
Methodological Considerations 453 
 454 
This study demonstrated that in lowlanders ascending to altitude, CBF does not increase until approximately 455 
5050 m (Figure 1). This CBF pattern is distinctly different from that demonstrated in individuals performing 456 
a similar ascent profile with concurrent acetazolamide prescription for acute mountain sickness prophylaxis 457 
(Willie et al., 2014a). However, given the maintenance of CDO2 despite unaltered CBF, and the disconnect 458 
between CBF at altitude and acute mountain sickness severity (Ainslie & Subudhi, 2014) there appears no 459 
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likely maladaptive consequences of the present CBF response to altitude. This is also likely the case for 460 
Sherpa, who despite reduced CDO2 present with no acute mountain sickness symptoms. 461 
 462 
In any high-altitude study, especially those comparing lowland native to high altitude native populations, it 463 
is important to consider: i) the level of acclimatization of the lowland group; and ii) the comparability of 464 
this acclimatization to that of the high altitude native population (i.e. Sherpa in the present study). In an 465 
attempt to match the extent of acclimatization between lowlanders and the Ascent Sherpa, the Ascent 466 
Sherpa descended to Kathmandu for 5-15 days prior to ascent with the lowlanders. As each group was 467 
tested 1 day following arrival at each altitude, neither group was likely acclimatized to a large extent at the 468 
time of each measurement. While a matching of acclimatization between groups cannot be explicitly 469 
confirmed, assessment of the hematological factors regulating CBF at altitude can provide inferential 470 
evidence for acceptable matching of acclimatization within the context of the present experimental design. 471 
In other words, there was close matching of [Hb] and CaO2 from 3400 m onwards. Other studies have 472 
observed that following >2 years of de-acclimatization Tibetans possess a lower [Hb] compared to 473 
lowlanders at low altitude (Liu et al., 2016); however, in the present study Sherpa [Hb] was elevated above 474 
lowlanders following 5-15 days of de-acclimatization in Kathmandu (Table 2). In lowlanders returning 475 
from altitude, [Hb] has been shown to return to sea-level values within one to two weeks (Ryan et al., 2014; 476 
Siebenmann et al., 2015) although this did not appear to be the case for the Sherpa population we tested. 477 
There was no correlation between the variability in duration (days) of de-acclimatization with [Hb] in 478 
Kathmandu (r<0.01; P=0.87). Whether a greater extent of chronic hypoxia in the Sherpa prolongs the 479 
presence of elevated [Hb] (or Hb mass) is currently unknown. Nevertheless, upon reaching 3400 m, there 480 
were no recorded hematological differences between groups. This indicates that differences in CBF and 481 
CDO2 throughout ascent cannot be attributed to [Hb], as it was similar between groups. 482 
 483 
In an attempt to provide greater insight into the regulatory mechanisms underlying the differences in CBF 484 
regulation between Sherpa and lowlanders observed herein, we utilized unpublished data from a prior 2008 485 
expedition to Nepal. While these data indicated there is no difference in cerebrovascular CO2 reactivity 486 
between Sherpa and Lowlanders, it is important to consider the small sample size of the Sherpa group from 487 
2008 (n=5). Nevertheless, a post hoc power calculation using the effect size derived from our CO2 reactivity 488 
data (d=0.27), while assuming a power of 0.8, indicates >200 subjects would be required in each group 489 
(lowlander and Sherpa) to observe a statistical difference in CO2 reactivity. While this indicates the lack of 490 
difference our data demonstrates is relatively robust, it is still important to note that the small sample size 491 
limits the certainty to which this comparison truly representative.  492 
 493 
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Typically, Sherpa are of smaller weight and stature than that of western counterparts (as in the present 494 
study), which may be cause to scale CBF to body size. Indeed, there appears to be a relationship between 495 
stature and brain weight, albeit quite modest and with a large standard error of the estimate (Heymsfield et 496 
al., 2009). If we apply the allometric equation derived by Heymsfield et al., 2009, we obtain an estimated 497 
brain mass of 1344±25 g for lowlanders, 1298±28 g for Ascent Sherpa, and 1309±23 g for Altitude Sherpa. 498 
Both the Ascent Sherpa (-3.5%) and Altitude Sherpa (-2.7%) estimates of brain mass are significantly lower 499 
than that of lowlanders (1-way ANOVA, P<0.01 for both). Under the assumption that these differences in 500 
brain mass are correct, it still remains unlikely that a 2-4% lower brain mass can explain the 24 and 27% 501 
lower CBF observed in our Ascent and Altitude Sherpa groups, respectively. Therefore, if there is indeed 502 
a lower cerebral metabolism in Sherpa at altitude, as speculated, this is likely primarily due to a signaled 503 
down-regulation of metabolic processes, versus that of a size principle (i.e., lower brain mass = lower 504 
cerebral metabolism). 505 
 506 
 507 
Significance and Implications 508 
 509 
Since their involvement in the attempted conquests of Mt. Everest in the early 1920’s, high altitude native 510 
Sherpa have been recognized for their exceptional performance at altitude and tolerance to hypoxia. In 511 
contrast to lowland native mountaineers who display deleterious consequences of ascent above 8000 m 512 
such as cortical atrophy and/or hyper-intensities (Garrido et al., 1993; Paola et al., 2008), Sherpa are 513 
unaffected in this regard (Garrido et al., 1996), indicating the presence of functional adaptations that confer 514 
protection to the brain. Therefore, it stands to reason that the lower CBF observed herein represents a 515 
positive adaptation. While lower CBF and CDO2 may indicate a hypometabolic adaptation in Sherpa, as 516 
speculated above, the potential implications of lower CBF extend beyond that of metabolic homeostasis. 517 
For example, lower CBF may predispose Sherpa to a lower risk of vasogenic edema and/or intracranial 518 
hypertension (Lawley et al., 2015; Sagoo et al., 2016) than lowlanders (Schoonman et al., 2008). This may 519 
be of particular importance at extreme altitudes (e.g. ≥8000 m) where lowlander CBF is reportedly 200% 520 





Sherpa have lived at high altitude for >25,000 years and possess specific physiological adaptations to the 526 
low atmospheric oxygen. In comparison to lowland natives, Sherpa perform exceptionally well at altitude 527 
from the perspective of physical performance, display a negligible incidence of altitude illness, and have 528 
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greater reproductive success. Many forms of altitude illness reside in the central nervous system and likely 529 
involve the cerebral circulation. Detecting the advantageous hypoxia tolerant adaptation possessed by the 530 
Sherpa may illuminate potential therapeutic targets in hypoxemic disorders, and further our basic 531 
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Table 1. Age and time at altitude for the Sherpa participants. 713 



















101 22 Thame 3800 16.5  113 43 Pangbouche 3985 43 
102 31 Thamo 3440 31  114 19 Khunde 3800 14 
103 30 Namche 3400 12  115 23 Darjeeling 2040 6 
104 25 Thamo 3440 25  116 26 Pheriche 4371 26 
105 38 Salleri 2300 24  117 18 Thame 3800 18 
106 39 Khumjung 3790 39  118 20 Thame 3800 16 
107 44 Khumjung 3790 44  120 18 Thame 3800 18 
108 26 Thamo 3440 21  121 20 Thame 3800 20 
109 44 Pangbouche 3985 41  122 23 Thamo 3440 23 
110 22 Thamo 3440 20  123 24 Thamo 3440 25 
111 59 Khunde 3840 59  124 20 Thamo 3440 10 
112 31 Pheriche 4371 16       
 714 
 715 
  716 
Cerebral blood flow in Sherpa at high altitude 
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Table 2. Arterial and venous blood data 717 
  Kathmandu (1400m) Namache (3400m) Pheriche (4371m) Pyramid (5050m) 
CaO2   Race: P=0.244; Altitude: P<0.001; Interaction: P=0.005 
(ml · dl-1) Lowlander 17.8±1.1† 17.3±1.0 16.7±0.9* 15.6±1.4* 
 Ascent Sherpa 19.3±1.1 17.3±1.4* 16.8±1.0* 15.7±1.4* 
SaO2   Race: P=0.152; Altitude: P<0.001; Interaction: P=0.809 
(%) Lowlander 95.4±1.2 87.4±2.7* 84.5±3.2* 79.0±4.9* 
 Ascent Sherpa 94.5±1.9 86.7±3.2* 82.5±4.5* 77.4±4.5* 
PaO2   Race: P=0.523; Altitude: P<0.001; Interaction: P=0.693 
(mmHg) Lowlander 77.0±6.5 51.8±4.1* 47.6±3.7* 41.2±4.4* 
 Ascent Sherpa 74.8±7.6 52.2±4.6* 46.7±4.5* 40.6±4.3* 
PaCO2   Race: P=0.050; Altitude: P<0.001; Interaction: P=0.011 
(mmHg) Lowlander 40.3±2.6 34.5±1.4* 32.2±1.6*† 29.9±1.9*† 
 Ascent Sherpa 39.8±1.6 35.4±2.3* 34.3±2.9* 32.1±2.7* 
pH  Race: P<0.001; Altitude: P<0.001; Interaction: P=0.918 
 Lowlander 7.42±0.02 7.44±0.02* 7.43±0.02 7.46±0.02* 
 Ascent Sherpa 7.40±0.01 7.41±0.02* 7.40±0.02 7.44±0.02* 
HCO3-   Race: P=0.111; Altitude: P<0.001; Interaction: P=0.002 
(mEq · L-1) Lowlander 26.33±1.42*† 23.57±1.21*† 21.55±1.34* 21.37±1.57* 
 Ascent Sherpa 24.55±1.24* 22.32±1.63* 21.47±1.83* 21.66±2.01* 
BEecf   Race: P=0.034; Altitude: P<0.001; Interaction: P=0.029 
(mEq · L-1) Lowlander 1.95±1.56*† -0.62±1.40*† -2.81±1.60* -2.39±1.93* 
 Ascent Sherpa -0.11±1.45* -2.18±1.83* -3.27±2.15* -2.67±2.17* 
[Hb]   Race: P=0.017; Altitude: P=0.012; Interaction: P=0.001 
(g · dl-1) Lowlander 13.56±0.80† 14.46±0.70* 14.44±0.52* 14.46±0.72* 
 Ascent Sherpa 14.83±0.92 14.50±0.75 14.85±0.89 14.81±0.65 
HCT   Race: P=0.020; Altitude: P=0.010; Interaction: P=0.001 
(%) Lowlander 39.90±2.39† 42.52±2.04* 42.48±1.54* 42.78±2.24* 
 Ascent Sherpa 43.64±2.69 42.64±2.20 43.64±2.62 43.66±2.17 
Venous viscosity   Race: P=0.240; Altitude: P<0.001; Interaction: P=0.004 
(cP) Lowlander 3.78±0.48† 4.41±0.30* 4.53±0.43* 4.78±0.36* 
 Ascent Sherpa 4.32±0.40 4.46±0.67 4.63±0.58 4.62±0.29 
Bolded Lowlander or Sherpa indicates a main effect of race, with the bolded group possessing a higher 718 
value 719 
* Significant difference from Kathmandu, P<0.05 720 
† Significant difference between Sherpa and Lowlander within an altitude, P<0.05 721 
CaO2, arterial oxygen content; SaO2, arterial oxyhaemoglobin saturation; PaO2, partial pressure of arterial 722 
oxygen; PaCO2, partial pressure of arterial carbon dioxide; HCO3-, bicarbonate ion; BEecf, base excess 723 
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Table 3. Influence of ascent to altitude on cerebrovascular parameters. 730 
  Kathmandu (1400m) Namache (3400m) Pheriche (4371m) Pyramid (5050m) 
ICA velocity  Race: P=0.105; Altitude: P<0.001; Interaction: P=0.021 
(cm · s-1) Lowlander 39.3±8.2 40.9±9.7 40.8±10.3 44.4±10.2* 
 Ascent Sherpa 37.2±5.8 32.1±5.6† 37.8±4.5 42.2±7.1 
ICA diameter  Race: P=0.315; Altitude: P<0.001; Interaction: P=0.270 
(mm) Lowlander 5.05±0.51 4.89±0.45* 4.85±0.47* 5.08±0.53 
 Ascent Sherpa 4.97±0.60 4.63±0.66* 4.74±0.40* 4.81±0.54 
ICA flow  Race: P=0.014; Altitude: P<0.001; Interaction: P=0.061 
(mL · min-1) Lowlander 236.2±49.3 229.0±50.5* 226.7±63.9 267.0±59.8* 
 Ascent Sherpa 215.2±32.4 165.8±50.3* 199.4±22.9 229.3±41.7* 
ICA DO2  Race: P=0.073; Altitude: P<0.001; Interaction: P=0.008 
(mL · min-1) Lowlander 42.1±0.2 39.4±8.0 36.0±12.9* 41.2±8.1 
 Ascent Sherpa 41.8±6.6 28.6±9.5*† 34.4±2.3 35.5±6.6 
VA velocity  Race: P=0.035; Altitude: P=0.001; Interaction: P=0.996 
(cm · s-1) Lowlander 24.3±5.4 26.1±6.1 25.4±7.7 29.6±7.3* 
 Ascent Sherpa 19.5±5.8 21.7±10.0 21.2±5.1 25.2±7.0* 
VA diameter   Race: P<0.001; Altitude: P=0.001; Interaction: P=0.033 
(mm) Lowlander 4.03±0.42 3.9±0.40 4.04±0.52 4.19±0.43 
 Ascent Sherpa 3.56±0.52† 3.16±0.57*† 3.36±0.57† 3.39±0.57† 
VA flow  Race: P=0.001; Altitude: P<0.001; Interaction: P=0.357 
(mL · min-1) Lowlander 94.3±30.0 96.8±30.1 98.3±34.7 122.3±35.0* 
 Ascent Sherpa 60.3±25.4 54.8±34.4 64.3±32.9 72.4±36.9 
VA DO2   Race: P=0.003; Altitude: P=0.091; Interaction: P=0.443 
(mL · min-1) Lowlander 16.7±5.3 16.7±5.0 16.4±5.8 19.0±5.7 
 Ascent Sherpa 12.2±4.7 9.9±6.3 11.5±5.6 12.6±6.2 
MAP  Race: P=0.017; Altitude: P<0.001; Interaction: P=0.002 
(mmHg) Lowlander 84.5±6.3 93.4±9.1* 93.9±8.6* 99.9±10.2* 
 Ascent Sherpa 95.2±9.2† 101.5±10.7† 100.7±9.6† 96.5±5.3 
Bolded Lowlander or Sherpa indicates a main effect of race, with the bolded group possessing a higher 731 
value 732 
* Significant difference from Kathmandu, P<0.05 733 
† Significant difference between Sherpa and Lowlander within an altitude, P<0.05 734 
DO2, delivery of oxygen; ICA, internal carotid artery; MAP, mean arterial pressure; VA, vertebral artery 735 
 736 
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Table 4. Comparison between lowlanders, the ascent Sherpa, and the altitude Sherpa following 742 
arrival at 5050m. 743 
  Lowlander Ascent Sherpa Altitude Sherpa  ANOVA 
CaO2 (ml · dl-1)  15.66±1.35 15.68±1.35 16.95±2.36  0.102 
SaO2 (%)  78.95±4.94 77.43±6.32 86.73±3.42*†  <0.001 
PaO2 (mmHg)  41.20±4.44 40.58±4.25 41.65±6.23  0.876 
PaCO2 (mmHg)  29.93±1.58 32.06±2.71* 31.88±2.44  0.020 
pH  7.46±0.02 7.44±0.02* 7.41±0.02*†  <0.001 
HCO3- (mEq · L-1)  21.37±1.57 21.66±2.01 20.26±1.56  0.123 
BEecf (mEq · L-1)  -2.39±1.93 -2.67±2.17 -4.35±1.69*  0.030 
[Hb] (g · dl-1)  14.46±0.72 14.81±0.65 15.94±1.03*†  <0.001 
HCT (%)  42.78±2.24 43.66±2.17 47.05±3.58*†  <0.001 
MAP (mmHg)  99.86±10.22 96.55±5.30 88.87±7.69*  0.006 
CVC (ml · min-1· mmHg-1)  7.99±1.74 6.41±1.64 6.54±1.99  0.047 
*denotes a significant difference from lowlanders; †, denotes a significant difference from the ascent Sherpa 744 
group.  CaO2, arterial oxygen content; SaO2, arterial oxyhaemoglobin saturation; PaO2, partial pressure of 745 
arterial oxygen; PaCO2, partial pressure of arterial carbon dioxide; HCO3-, bicarbonate ion; BEecf, base 746 
excess extracellular fluid; [Hb], haemoglobin concentration; HCT, haematocrit; MAP, mean arterial 747 
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Figure 1. Regional cerebral blood flow and cerebral oxygen delivery upon ascent to 5050 m in 764 
lowlanders and Sherpa. For all panels lowlanders are denoted by the filled circle symbol (•), and Sherpa 765 
by the open square symbol (⁍). A. Internal carotid artery (ICA) flow in lowlander and Sherpa. ICA flow 766 
was reduced across groups at 3400 m (marginal means, P=0.01) and increased across groups at 5050 m 767 
(marginal means, P=0.02). B. Vertebral artery (VA) flow in lowlander and Sherpa. VA flow was increased 768 
across groups at 5050 m (marginal means, P<0.01). C. Global cerebral blood flow (gCBF) in lowlander 769 
and Sherpa. gCBF was reduced across groups at 3400 m (marginal means, P=0.038) and increased across 770 
groups at 5050 m (marginal means, P<0.01). D. Cerebral oxygen delivery (CDO2) in lowlander and Sherpa. 771 
CDO2 was lower in Sherpa compared to lowlanders at 3400 m (P<0.01), 4371 m (P=0.03), and 5050 m 772 
(P<0.01). While lowlander CDO2 was maintained across ascent, Sherpa CDO2 decreased from Kathmandu 773 
values at 3400 m (P<0.01) and 4731 m (P=0.04). In all panels, the % change from Kathmandu values for 774 
lowlanders and Sherpa throughout ascent are presented in the right figures.* Denotes a significant change 775 
from Kathmandu values (P<0.05) 776 










Figure 2. Cerebral blood flow distribution in lowlanders and Sherpa upon ascent and following 784 
acclimatization. The presented data are global cerebral blood flow (gCBF) with open bars for the 785 
lowlanders, grey bars for the ascent sherpa and a black bar for the altitude sherpa. Overlayed on the gCBF 786 
data, a patterned bar, is an estimate of bilaterial VA flow (2 · unilateral VA flow), with the estimated 787 
%contribution of VA flow to gCBF denoted above each time point. For the ascent protocol a 2-way 788 
ANOVA was used for statistical comparisons (Factors: Race and Altitude). Their was a main effect of Race 789 
(P=0.018) with the %CBF distribution to the posterior circulation less in Sherpa across altitudes. Following 790 
2-weeks at 5050 m, the three groups (right side of figure) were compared using a 1-way ANOVA. Both the 791 
ascent Sherpa (P<0.01) and altitude Sherpa (P<0.01) had lower VA distribution than lowlanders following 792 
arrival at 5050 m.  793 
 794 




Figure 3. Covariate analysis of cerebral blood flow regulation in sherpa and lowlanders. This figure 796 
depicts the estimated marginal means (±standard error) and model output for the linear mixed effects model 797 
analysis of gCBF without (Panel A) and with (Panel B) adjustment for important factors in the control of 798 
gCBF at altitude. Following inclusion of covariates into the statistical model, there is an interaction between 799 
altitude and race, with post-hoc analysis (Bonferroni corrected) indicating the gCBF was lower in Sherpa 800 
compared to lowlanders at all time points. Each table includes the overall model equation and the individual 801 
coefficients for each of the fixed effects (altitude and race). Subjects were included as a random effect. 802 
gCBF, global cerebral blood flow; MAP, mean arterial pressure. 803 
 804 





Figure 4. Cerebral blood flow and oxygen delivery in acclimatized lowlanders, Sherpa following 807 
ascent, and Sherpa recruited at altitude. In all panels lowlanders are denoted by the filled circle symbol, 808 
Sherpa that took part in the ascent with the open square symbol, and Sherpa who were recruited at altitude 809 
by the filled triangle. ICA, internal carotid artery; VA, vertebral artery; gCBF, global cerebral blood flow; 810 
CDO2, cerebral oxygen delivery. Horizontal bars indicate a significant difference from lowlanders. 811 
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Figure 5. Lowlander and Sherpa cerebrovascular CO2 reactivity. The presented cerebrovascular 815 
reactivity data are the relative reactivity (i.e. %change) values for lowlanders and Sherpa collected at 5050 816 
m in 2008. The hyperoxic rebreathe technique was used for these tests [Previously described: (Fan et al., 817 
2010)]. There is no difference in CO2 reactivity between sherpa and acclimatized lowlanders as determined 818 
by the non-parametric Mann Whitney U Test (P=0.77). 819 
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